Abstract:134 Background: Chemoradiation is the standard neoadjuvant treatment for locally advanced rectal cancer. Microsatellite stable (MSS)/ mismatch repair proficient (pMMR) rectal cancer rarely responds to immune checkpoint inhibitor monotherapy, but combination with chemoradiation may improve sensitivity of MSS/pMMR tumors by inducing immune-stimulatory effects. Therefore, we aimed to investigate the efficacy and safety of patients treated with neoadjuvant preoperative short-course radiation followed by envafolimab plus CAPEOX for MSS/pMMR locally advanced rectal cancer. Methods: This is an open-label, single-center, phase ¢ò study. Patients (pts) with locally advanced rectal adenocarcinoma with MSS/pMMR were eligible. MMR protein expression was tested by immunohistochemistry (IHC) £¬and MSI status was confirmed by NGS (next generation sequencing). All pts included in this study underwent neoadjuvant short-course radiation (total dose of 5¡Á5Gy) in the first week after enrollment, then followed by 6 cycles of envafolimab (anti-PD-L1 inhibitor,150mg, d1, subcutaneous injection, QW) plus 2 cycles of CAPEOX in the next six weeks, and subsequently underwent total mesorectal excision (TME) in the ninth week. The primary endpoint is pathological complete response rate. Secondary endpoints include tumor regression grade (TRG), 3 year disease free survival, overall survival, toxicity, and quality of life (QoL). Results: This study intends to recruit 32 pts, and a total of 21 pts were enrolled from January 2022 to September 2022. Overall median age was 67 (42-79) years. 12 pts completed study designed treatment protocol (envafolimab plus CAPOX) followed with TME procedures, and 9 pts are still undergoing neoadjuvant treatment. All 12 pts achieved major partial response (MPR) evaluated by diffusion-weighted magnetic resonance imaging (DW-MRI), and 8 pts (8/12,76.6%) achieved pCR. During neoadjuvant treatment period, 20 pts (20/21, 95.2%) presented with treatment-related AEs (TRAEs) of any grade, 18 pts (18/21, 85.7%) had grade 1-2 and one each pts had grade 3 and 4 thrombocytopenia (2/21, 9.5%). The most common TRAEs were sensation of rectal tenesmus. Conclusions: Neoadjuvant preoperative short-course radiation followed by envafolimab plus CAPEOX in MSS/pMMR locally advanced rectal cancer achieved a promising pathologic response. Meanwhile, this combination neoadjuvant therapy is safe and worthy of application to clinical practice. (Funded by Sir Run Run Shaw Hospital Zhejiang University School of Medicine.) Clinical trial information: NCT05216653 .

Efficacy and Safety of Neoadjuvant Intensity-Modulated Radiotherapy with Concurrent Capecitabine for Locally Advanced Rectal Cancer

Comparison of Two Different Neoadjuvant Chemoradiatiotherapy Regimens for Locally Advanced Rectal Cancer: Results of a Phase II, Multicenter, Randomized Trial.

Phase II Study of Neoadjuvant Short-Course Radiotherapy Combined with CAPEOX Plus Envafolimab in Patients with Microsatellite Stable Locally Advanced Rectal Cancer: Updated Results of PRECAM Study.

Feasibility Of Relatively Low Neoadjuvantradiation Doses For Locally Advanced Rectal Cancer: A Propensity Score-Matched Analysis

Long-course neoadjuvant chemoradiotherapy with versus without a concomitant boost in locally advanced rectal cancer: a randomized, multicenter, phase II trial (FDRT-002)

Efficacy of the radiotherapy combined with oxaliplatin and capecitabine in the treatment of local advanced rectal cancer

Efficacy of Preoperative Neoadjuvant Simultaneous Integrated Boost IMRT Radiation Therapy Combined with Preoperative Chemotherapy for Locally Advanced Rectal Cancer: A Prospective II Clinical Study

Compliance and Safety of Neoadjuvant Intensity Modulated Radiotherapy (imrt) with Concurrent Capecitabine for Locally Advanced Rectal Cancer: Updated Results from A Phase Ii Trial (Chictr-Tnc-10001094).

Efficacy of Preoperative Neoadjuvant Simultaneous Integrated Boost Intensity?modulated Radiotherapy Combined with Preoperative Chemotherapy for Locally Advanced Rectal Cancer:A Phase Ⅱ Clinical Study

Postoperative Capecitabine With Concurrent Intensity-Modulated Radiotherapy Or Three-Dimensional Conformal Radiotherapy For Patients With Stage Ii And Iii Rectal Cancer

Preoperative Volumetric Modulated Arc Therapy With Simultaneous Integrated Boost for Locally Advanced Distal Rectal Cancer

[Efficacy of neoadjuvant radiochemotherapy in treatment of locally advanced low rectal cancer]

Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study

Neoadjuvant Chemotherapy with Capecitabine Combined with Oxaliplatin for Mid-Low Locally Advanced Rectal Cancer with Negative Mesorectal Fascia: Long-term Outcomes of a Prospective Trial (PKUCH-R03 Trial).

Efficacy and safety of neoadjuvant preoperative short-course radiation followed by envafolimab plus CAPEOX in microsatellite stable (MSS)/mismatch repair proficient (pMMR) locally advanced rectal cancer.

A retrospective cohort study of neoadjuvant chemoradiotherapy combined with immune checkpoint inhibitors in locally advanced rectal cancer

Preoperative Concomitant Boost Intensity-Modulated Radiotherapy with Oral Capecitabine in Locally Advanced Mid-Low Rectal Cancer: a Phase II Trial.

Clinical efficacy of preoperative SIB-IMRT for 26 cases of locally-advanced low rectal cancer

Neoadjuvant Sandwich Treatment with Oxaliplatin and Capecitabine Administered Prior To, Concurrently With, and Following Radiation Therapy in Locally Advanced Rectal Cancer: a Prospective Phase 2 Trial.

Toxicity Evaluation Of Capecitabine Concurrent Chemoradiotherapy For Stage Ii And Iii Rectal Cancer

Outcome of Locally Advanced Rectal Cancer Patients Treated with Radical Surgery Followed by Concurrent Capecitabine and Radiotherapy